From the scenario, determine the Market value of the firm's equity, the market value of the firm's debt, the cost of equity (required rate of return), cost of debt (yield to maturity on existing debt) and the corporate tax rate.

Financial Reporting, Financial Statement Analysis and Valuation
8th Edition
ISBN:9781285190907
Author:James M. Wahlen, Stephen P. Baginski, Mark Bradshaw
Publisher:James M. Wahlen, Stephen P. Baginski, Mark Bradshaw
Chapter10: Forecasting Financial Statement
Section: Chapter Questions
Problem 8QE
icon
Related questions
icon
Concept explainers
Question

From the scenario, determine the Market value of the firm's equity, the market value of the firm's debt, the cost of equity (required rate of return), cost of debt (yield to maturity on existing debt) and the corporate tax rate. 

Vigour Pharmaceuticals Ltd. is considering investing in a new production line for its pain-reliever medicine for
individuals who suffer from cardio vascular diseases. The company has to invest in equipment which costs $2,500,000
and will be depreciated under the MACRS system for a 5-year asset class. It is expected to have a scrap value of $700,000
at the end of the project. Other than the equipment, the company needs to increase its cash and cash equivalents by
$100,000, increase the level of inventory by $30,000, increase accounts receivable by $250,000 and increase account
payable by $50,000 at the beginning of the project. Vigour Pharmaceuticals expect the project to have a life of five years.
The company would have to pay for transportation and installation of the equipment which has an invoice price of
$450,000. The company has already invested $75,000 in Research and Development and therefore expects a positive
impact on the demand for the new pain-reliever. Expected annual sales for the product in the first three years are $600,000
and $850,000 in the following two years. The variable costs of production are projected to be $267,000 per year in years
one to three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of the project. The
introduction of the new line of pain reliever will cause a net decrease of $50,000 in profit contribution due to a decrease in
sales of the other lines of pain relievers produced by the company. By investing in the new product line Vigour
Pharmaceuticals would have to use a packaging machine which the company already has. It is fully depreciated and could
be sold at the end of the project for $350,000 after-tax in the equipment market. The company's financial analyst has
advised Vigour Pharmaceuticals to use the weighted average cost of capital as the appropriate discount rate to evaluate the
project. The following information about the company's sources of financing is provided below:
a. The company will contract a new loan in the sum of $2,000,000 that is secured by machinery and the loan has an
interest rate of 6 percent.
b. Vigour Pharmaceuticals has also issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2 percent per issue.
c. The company's preferred stock pays an annual dividend of 4.5 percent and is currently selling for $60, and there are
100,000 shares outstanding.
d. There are 300,000 million shares of common stock outstanding, and they are currently selling for $21 each. The beta on
these shares is 0.95.
Transcribed Image Text:Vigour Pharmaceuticals Ltd. is considering investing in a new production line for its pain-reliever medicine for individuals who suffer from cardio vascular diseases. The company has to invest in equipment which costs $2,500,000 and will be depreciated under the MACRS system for a 5-year asset class. It is expected to have a scrap value of $700,000 at the end of the project. Other than the equipment, the company needs to increase its cash and cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts receivable by $250,000 and increase account payable by $50,000 at the beginning of the project. Vigour Pharmaceuticals expect the project to have a life of five years. The company would have to pay for transportation and installation of the equipment which has an invoice price of $450,000. The company has already invested $75,000 in Research and Development and therefore expects a positive impact on the demand for the new pain-reliever. Expected annual sales for the product in the first three years are $600,000 and $850,000 in the following two years. The variable costs of production are projected to be $267,000 per year in years one to three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of the project. The introduction of the new line of pain reliever will cause a net decrease of $50,000 in profit contribution due to a decrease in sales of the other lines of pain relievers produced by the company. By investing in the new product line Vigour Pharmaceuticals would have to use a packaging machine which the company already has. It is fully depreciated and could be sold at the end of the project for $350,000 after-tax in the equipment market. The company's financial analyst has advised Vigour Pharmaceuticals to use the weighted average cost of capital as the appropriate discount rate to evaluate the project. The following information about the company's sources of financing is provided below: a. The company will contract a new loan in the sum of $2,000,000 that is secured by machinery and the loan has an interest rate of 6 percent. b. Vigour Pharmaceuticals has also issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually and matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2 percent per issue. c. The company's preferred stock pays an annual dividend of 4.5 percent and is currently selling for $60, and there are 100,000 shares outstanding. d. There are 300,000 million shares of common stock outstanding, and they are currently selling for $21 each. The beta on these shares is 0.95.
Other relevant information is as follows:
į. The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent
using the returns on stocks and Treasury bonds.
ii. Vigour Pharmaceuticals has a marginal tax rate of 35 percent. In the event of a negative taxable income, the tax is
computed as usual and is reported as a negative number, indicating a reduction in loss after tax.
As a recent graduate of a university, The General Manager of the company has hired you to work alongside the Financial
Controller of the company to help determine whether the company should invest in the new product line. He has provided
you with the following questions to guide you in your assessment of the project and to present your findings to the
Company.
Transcribed Image Text:Other relevant information is as follows: į. The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds. ii. Vigour Pharmaceuticals has a marginal tax rate of 35 percent. In the event of a negative taxable income, the tax is computed as usual and is reported as a negative number, indicating a reduction in loss after tax. As a recent graduate of a university, The General Manager of the company has hired you to work alongside the Financial Controller of the company to help determine whether the company should invest in the new product line. He has provided you with the following questions to guide you in your assessment of the project and to present your findings to the Company.
Expert Solution
steps

Step by step

Solved in 3 steps with 2 images

Blurred answer
Knowledge Booster
Cost of Capital
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Financial Reporting, Financial Statement Analysis…
Financial Reporting, Financial Statement Analysis…
Finance
ISBN:
9781285190907
Author:
James M. Wahlen, Stephen P. Baginski, Mark Bradshaw
Publisher:
Cengage Learning